Related Experiment Video

Updated: Aug 10, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance

Sonia Bortolotti1, Silvia Angelucci1, Luca Montemurro2

  • 1BIOGENERA SpA, R&D Department, 40064 Bologna, Italy.

Cancers
|February 11, 2023
PubMed

Insights

A novel therapeutic oligonucleotide, BGA002, effectively targets MYCN in small-cell lung cancer (SCLC), inhibiting tumor growth and overcoming drug resistance. This precision medicine approach shows promise for improving survival in MYCN-amplified SCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Precision Medicine

Background:

  • Small-cell lung cancer (SCLC) is highly aggressive with poor prognosis, often linked to MYC family alterations.
  • MYCN alterations are associated with poor prognosis and immunotherapy failure in SCLC.
  • MYCN is an attractive but undruggable target for traditional therapies.

Purpose of the Study:

  • To develop and evaluate BGA002, an MYCN-specific antigene-PNA oligonucleotide, as a novel precision medicine for MYCN-related SCLC.
  • To assess BGA002's efficacy in inhibiting MYCN expression, inducing apoptosis, and overcoming drug resistance in SCLC.
  • To investigate the molecular mechanisms underlying BGA002's effects and its impact on survival in preclinical models.

Main Methods:

  • Development of an MYCN-specific antigene-PNA oligonucleotide (BGA002).
  • In vitro assessment of BGA002's effects on SCLC cell lines, including MYCN expression, cell growth, apoptosis, and drug resistance.
  • Analysis of downstream molecular pathways, including mTOR and autophagy.
  • In vivo evaluation of BGA002's efficacy and survival benefit in MYCN-amplified SCLC mouse models.

Main Results:

  • BGA002 specifically and potently inhibited MYCN expression in SCLC cells.
  • BGA002 induced cell-growth inhibition and apoptosis, while overcoming multidrug resistance.
  • Therapeutic effects were mediated by mTOR pathway blockade and autophagy reactivation.
  • BGA002 reverted an MYCN-related SCLC gene signature (CNTFR, DLX5, TNFAIP3).
  • Systemic BGA002 treatment significantly increased survival in MYCN-amplified SCLC mouse models, reducing tumor vascularization and overcoming drug resistance.

Conclusions:

  • BGA002 represents a promising novel precision medicine for MYCN-related SCLC.
  • The antigene-PNA oligonucleotide approach effectively targets the previously undruggable MYCN.
  • BGA002 demonstrates significant preclinical efficacy, warranting clinical investigation for SCLC treatment.
Keywords:
MYCNmTORsmall-cell lung cancertargeted therapy

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

414

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K